A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Have Trusted Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 358
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2024 IOL Market Report: Global Analysis for 2023 to 2029, March, 2024
The “2024 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
3/24/2025
BreakingCataractDealsEquipmentFLACSSurgical
Alcon Agrees to Buy Lensar in Deal Worth up to $430 Million
Alcon announced March 24 that it had entered into a definitive agreement to acquire Lensar, including its Ally femtosecond laser cataract system, its Streamline software, and the Lensar legacy lase...
3/21/2025
BreakingDealsRegulationRetinaUveitis
US FDA Expands Label for Iluvien to Include Chronic Non-infectious Posterior Uveitis
ANI Pharmaceuticals, of Baudette, Minnesota, announced March 14 that the US FDA had approved an expanded label for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) to include treatment...
3/21/2025
BreakingChinaRegulationThyroid Eye Disease
Chinese Regulators Approve Innovent’s Sycume for Thyroid Eye Disease
China’s Innovent Biologics announced March 14 that Chinese regulators had approved Sycume, a recombinant anti-insulin-like growth factor 1 receptor antibody for thyroid eye disease (TED). Innovent ...
3/21/2025
BreakingDealsDry EyeGlaucomaPharma
Eyenovia Weighs Potential All-Stock Reverse Merger with Betaliq
Eyenovia, of New York, reported March 20 that it was contemplating an all-stock reverse merger with Betaliq, of Tampa, Florida. The new, publicly listed company would combine Betaliq’s EyeSol water...
3/20/2025
Clinical TrialFundingNewsletterRegulationStudy
Changes in NIH Grant Rules Threaten to Ripple Through Eye Disease Research
Any changes to the rules that accompany US government research grants could affect eye research in the US in a big way. The US government awards an average of $1.1 billion a year in grants to resea...
3/21/2025
BreakingLow VisionRetina
Thomas Panek to Lead Lighthouse Guild
Lighthouse Guild announced March 18 that it had appointed Thomas Panek as its new president and CEO, effective April 1. Panek replaces Calvin Roberts, MD, who has led the nonprofit since April 2020...
3/21/2025
BiosimilarsBreakingDealsEuropeRetina
Xbrane to Sell Part of Company to Alvotech, Plans to Keep Ximluci
Sweden’s Xbrane will sell its Cimzia biosimilar candidate and parts of its organization to Iceland’s Alvotech for SEK 275 million ($27.1 million), the two companies reported March 20. Xbrane will r...
3/21/2025
BreakingDealsLow VisionRetina
Vivani Now Intends to Spin Out Cortigent, Developer of Orion Implant
Vivani Medical, of Alameda, California, reported March 12 that it intends to spin off its Cortigent neurostimulation business, formerly Second Sight Medical Products, into a fully independent, publ...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.
This website uses cookies to ensure you get the best experience. By continuing to use our website, you consent to our use of cookies.